Intranasal Chlorpheniramine Maleate for the treatment of COVID-19: Translational and Clinical Evidence

Recently, the nasal cavity has been highlighted as an ideal route of administration for interventions it is portal entry severe acute respiratory syndrome coronavirus (SARS-CoV-2). The present study aimed to demonstrate feasibility and efficacy intranasally administered Chlorpheniramine Maleate (CPM) spray treat disease 2019 (COVID-19). Methods: used a two-phase, non-clinical clinical approach. phase evaluated CPM’s antiviral activity against SARS-CoV-2 delta (B.1.617.2) strain via highly differentiated three-dimensional in vitro model normal, human-derived tracheal/bronchial epithelial cells. CPM was tested duplicate inserts tissue models human airway. Virus yield reduction assays measured on day six after infection. For phase, COVID-19 symptomatic (polymerase chain reaction positive) patients were recruited assigned 7-day treatment (n=32) or placebo (PLB; n=13). Close safety monitoring all conducted before administering drug. primary outcomes monitored time symptom resolution (days), progression hospitalization, emergency room visits, symptoms severity using visual analog scale (VAS) 1-10 (no worst symptoms). Results: virus yielded assay such that solution log value 2.69 Remdesivir 0.12, demonstrating much high CPM. Results VAS scores between groups evident two days (day 3). group significantly lower (P<0.001) starting from three compared with one. In contrast, there no statistically significant (P>0.05) changes PLB during window. No subjects intervention hospitalized, while required hospitalization (15.4%; X2=5.15, P=0.023). Besides some mild discomfort felt by immediately applying spray, participants reported neither adverse reactions nor side effects. Conclusion: If taken together, results two-phase point towards conclusion agent can be effectively.